Lexicon Pharmaceuticals, Inc. (LXRX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Lexicon Pharmaceuticals reported revenue of $49.8M, up 60.2% from $31.1M the year before. Net income was -$50.3M (a -101.1% net margin), or -$0.14 per diluted share. Gross margin was 99.4% and operating margin was -98.2%. Operating activities generated -$67.9M of cash. At fiscal year end, Lexicon Pharmaceuticals held $185.0M in total assets against $77.4M in total liabilities, including $34.3M of cash and equivalents.
Open the full interactive Lexicon Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Lexicon Pharmaceuticals Key Stats
| Share Price | $1.61 |
|---|---|
| Market Cap | $704.6M |
| Revenue YoY Growth | +60.2% |
| 52-Week Range | $1.14 – $2.64 |
| Shares Outstanding | 437.7 million (basic, 2026 Q2) |
Lexicon Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $24.0M | $298,000 | $139,000 | $1.2M | $31.1M | $49.8M |
| Cost of Goods Sold | $1.9M | $0 | $0 | $85,000 | $616,000 | $274,000 |
| Gross Profit | $22.1M | $298,000 | $139,000 | $1.1M | $30.5M | $49.5M |
| Operating Income | -$47.8M | -$87.1M | -$100.8M | -$171.8M | -$197.1M | -$48.9M |
| Pre-Tax Income | -$58.6M | -$87.8M | -$101.9M | -$177.1M | -$200.4M | -$50.3M |
| Income Tax | — | — | — | $0 | $0 | — |
| Net Income | -$58.6M | -$87.8M | -$101.9M | -$177.1M | -$200.4M | -$50.3M |
| Diluted EPS | -$0.53 | -$0.60 | — | -$0.80 | -$0.63 | -$0.14 |
Lexicon Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $14.2M | $5.5M | $21.1M | $692,000 |
| Net Income | -$12.8M | -$15.5M | -$1.0M | -$31.8M |
| Diluted EPS | -$0.04 | -$0.04 | — | -$0.07 |
Lexicon Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $126.3M | $64.1M | $46.3M | $22.5M | $66.7M | $34.3M |
| Current Assets | $157.7M | $88.9M | $140.9M | $176.5M | $246.2M | $101.9M |
| Total Assets | $203.8M | $136.9M | $194.3M | $229.4M | $298.4M | $185.0M |
| Current Liabilities | $46.8M | $22.1M | $23.2M | $31.5M | $45.2M | $20.9M |
| Total Long-Term Debt | $12.3M | $1.2M | $48.6M | $99.5M | $100.3M | $54.0M |
| Total Liabilities | $47.4M | $23.3M | $77.2M | $136.3M | $152.5M | $77.4M |
| Shareholders' Equity | $156.4M | $113.6M | $117.1M | $93.1M | $145.9M | $107.5M |
Lexicon Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$143.0M | -$87.0M | -$88.9M | -$161.9M | -$178.8M | -$67.9M |
| Cash From Investing | $380.8M | $2.1M | -$71.1M | -$49.9M | -$15.4M | $113.0M |
| Cash From Financing | -$147.6M | $22.7M | $142.2M | $188.0M | $238.3M | -$48.5M |
| Free Cash Flow | -$143.1M | -$88.2M | -$90.2M | -$162.4M | -$179.8M | -$67.9M |
Figures from Lexicon Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Lexicon Pharmaceuticals financials page for every line item.
Lexicon Pharmaceuticals Company Profile
| Ticker | LXRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | The Woodlands, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001062822 |
Frequently Asked Questions
What was Lexicon Pharmaceuticals' revenue in fiscal 2025?
Lexicon Pharmaceuticals (LXRX) reported revenue of $49.8M for fiscal 2025.
What is Lexicon Pharmaceuticals' annual revenue history?
Lexicon Pharmaceuticals' annual revenue by fiscal year: 2020: $24.0M; 2021: $298,000; 2022: $139,000; 2023: $1.2M; 2024: $31.1M; 2025: $49.8M.
What was Lexicon Pharmaceuticals' net income in fiscal 2025?
Lexicon Pharmaceuticals reported net income of -$50.3M for fiscal 2025.
What was Lexicon Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Lexicon Pharmaceuticals' diluted EPS was -$0.14 for fiscal 2025 (adjusted for any later stock splits).
What was Lexicon Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Lexicon Pharmaceuticals reported revenue of $692,000.
How much debt does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals reported $54.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Lexicon Pharmaceuticals are outstanding?
Lexicon Pharmaceuticals reported a weighted average of 437.7 million basic shares outstanding in 2026 Q2.
What is Lexicon Pharmaceuticals' market cap?
Based on its latest closing price, Lexicon Pharmaceuticals (LXRX) has a market capitalization of about $704.6M.
When does Lexicon Pharmaceuticals' fiscal year end?
Lexicon Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Lexicon Pharmaceuticals headquartered?
Lexicon Pharmaceuticals lists its business address in The Woodlands, Texas in its SEC filings.